|
African Journal of Biomedical Research
Ibadan Biomedical Communications Group
ISSN: 1119-5096
Vol. 11, Num. 1, 2008, pp. 27-31
|
TOXICOSIS OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS IN RATS
African Journal of Biomedical Research, Vol. 11, No. 1, Jan, 2008, pp. 27-31
Full Length Research Article
HAART and Lipid Metabolism
in a Resource Poor West African Setting
1,2Ogundahunsi O.A, 1,2Oyegunle V.A, 1,4Ogun
S. A, 1,5Odusoga O.L and 1,3Daniel O.J.
1Center for Special Studies, Community Medicine
Department, Obafemi Awolowo College of
Health sciences.(OACHS)
Departments of 2Chemical
Pathology ,3Community Medicine ,4Medicine, 5Obstetrics
& Gynaecology, Obafemi Awolowo College of Health sciences,Olabisi Onabanjo University,
Sagamu, Ogun State, Nigeria.
*Address
for Correspondence: E-mail:
Received: May
2007
Accepted
(Revised): October
2007
Published: January
2008
Code Number: md08004
ABSTRACT
Highly
active antiretroviral therapy (HAART) confers several benefits, including
reduction in viral load and longevity in HIV positive patients. However,
Metabolic and morphological complications have been increasingly reported among
patients in the advanced industrialized countries receiving chronic HAART up to
10-20years. We report occurrence of hyperlipidaemia in subjects on HAART in a
West African Community. The CD4+ cell count and fasting lipid profile were
estimated in One hundred and ten (110) HIV positive patients attending the HIV
clinic of Obafemi Awolowo College of Health Sciences, Sagamu. Fifty five
subjects served as the study subjects and were selected randomly from the
patients on triple combination therapy of ARV medication for a minimum of 3
years and matched for age and sex with the control group (55) of those who were
not on ARV medication. All the subjects were symptomatic grade 3 or 4 WHO
classification. The CD4 count of the study was 355.11cells/mm3±
185.0 and was statistically significantly higher than the CD4 count of the
control subjects which was 177.95 cells/mm3 ± 59.1
(P<0.05). The mean values for VLDL, LDL, Cholesterol, and triglyceride
concentrations were 32.9mg/dl ±8.9, 75.9mg/dl ± 45.8,
142.3mg/dl ± 48.6, 163.6mg/dl ±44.5 in study group respectively
and were statistically significantly higher than 30.3mg/dl ± 1.2,
48.9mg/dl ± 34.4, 114.6 mg/dl ± 35.8, 150.5mg/dl ± 37 in
the control group. (P<0.05) The mean concentration of HDL of 36.0 mg/dl ±
13 in the control subjects was significantly higher than 29.7mg/dl ± 8.9
in the study (P>0.05). The prevalence of hypertryglyceridemia (>200mg/dl)
was 15%.in the study group and 2.5%.in the control.
Key words: dyslipidaemia, limited resource settings, hypertryglyceremia,
hypercholesteremia, HAART, lipid concentration
INTRODUCTION
The
benefits of antiretroviral therapy can be striking when compared with the HIV
epidemic in the nineteen nineties. HAART confer several benefits, such as
virological, immunological, clinical, and survival, to HIV positive patients.
(Schapiro and Coller 1996, Palella 1998.) As a result of antiretroviral
therapy, HIV-infected persons can expect a prolonged and perhaps even normal
survival duration. (Dominc et al 2006 )
However,
many unrelated clinical management challenges still exist.
One
of such challenges is the decision to start therapy. (Riddler et al
2003) This is largely because the effectiveness of treatment must be balanced
against the possibility of toxicity. For many patients and providers, concern
about long-term toxicity weighs most heavily in the decision to defer or delay
initiation of antiretroviral therapy. The side effects that cause most concern
are morphological and metabolic complications. (Carr 2000.). Metabolic
complications include dyslipideamia, hyperinsulinemia, hyperglycemia, insulin
resistance, lactic acidosis, osteonecrosis and osteoporosis.(Carr 1998, 1999, &
2000, Behrens and Schmidt 2005) These conditions vary from patient to patient
and the pathophysiology of the occurrence of these metabolic alterations is not
well understood. (Massip 1999, Behrens and Schmidt 2005).Several possible
factors have been identified as effecting the development of these metabolic
complications. White race, age of patient, and affluence are some of the
factors that have been suggested by several groups as playing a role in
determining the metabolic changes .(Kotler 1999b,Boyle 2002 ) Therefore, an
understanding of how a resource limited population is affected by HAART will
have a profound effect on treatment decisions.
MATERIALS AND
METHODS
Free
antiretroviral drug programme for HIV/AIDs patients started in July 2000 at the
centre for special studies (CSS) Sagamu, Ogun state Nigeria. The centre is
currently located at the infectious disease clinic of the department of
Community Medicine and Primary Care of Olabisi Onabanjo University Teaching
Hospital Sagamu, Nigeria.
The
CD4 and fasting lipid profile was estimated in one hundred and ten HIV positive
patients attending the HIV clinic. Fifty five subjects who served as the study
subjects were picked randomly from the patients on free triple combination
therapy of ARV medication for a minimum of 3 years and matched for age and sex
in the control group (55) of those who are not on ARV medication. All the
subjects are AIDS or symptomatic HIV patients mainly in Group 3 and 4 of WHO
classification. They presented with thrush, cough, rashes, unexplained fever
for more than two weeks, and other opportunistic infections. In addition the
patients had a CD4 count of below 200mm3 and a viral load of more
than 20,000mm3.The subjects receiving HAART medication were managed
with combination of at least 3 antiretroviral drugs from 2 of the 3 groups of
antiretroviral drug. Viz: The protease inhibitors (PI), The Nucleoside Reverse
Transcriptase Inhibitors (NRTI), and the Non Nucleoside Reverse Transcriptase
Inhibitors. (NNRTI)
The
two arm of drugs given to the patients were combined thus
ARM
1 = 1PI + 2NRTI
Or
ARM
2 = 1NNRTI + 2NRTI.
Laboratory
methods
The
CD4 T cells: were determined by the
Dynal beads manual method. Concentrations of total cholesterol, High density
lipoprotein cholesterol(HDL-C) and triglycerides were measured using enzymatic
assays.
Triglycerides: Triglyceride
estimation was made by the enzymatic colorimetric test of glycerol phosphate
oxidase method. (Tietz, 1999)
High
density lipoprotein-cholesterol: Low
density lipoproteins (LDL and VLDL) and chylomicron fractions were precipitated
quantitatively by the action of phosphotungstic acid in the presence of
magnesium ions. After centrifugation, the cholesterol concentration in the HDL
fraction which remains was determined by the enzymatic colorimetric method.
(Tetz, 1999)
Total
Cholesterol: This was carried out by
the enzymatic colorimetric method.(Clinical laboratory Diagnostics 1998)
Low
density lipoprotein cholesterol levels:
were calculated from total cholesterol, HDL-C, and triglyceride by the
Friedewald equation (Friedewald et al 1972)
Quality
control: control samples were assayed
along with the test samples and assay batches with controls values that fall
outside the established laboratory values were repeated.
RESULTS
The
study populations were mainly adults with the mean age of 40.4 ± 10.9 in
the HAART group and 36.9 ± 9.3 in the control group.(Table 1) There were
improvements in the weight and consequently in the body mass index of the two
groups after the initiation of HAART in the study group and the treatment of
opportunistic infection in the control group.(Table 2) However the weight
increase in the study group on HAART were statistically significantly higher
than in the control.
The
CD4 cell count and absolute lymphocyte count in the HAART group was
significantly different from the control group, thus showing the effects of
HAART in improving the immunological properties of the subjects. Similarly the
concentrations of the lipid concentration in the HAART group was significantly
elevated than in the control. (Table 3).
The
prevalence of hypertryglycaeraemia and hypercholesteronaemia was 23.1% in the
ARM one group which contains one protease inhibitor. The prevalence of
hypertryglyceridemia (>200mg/dl) was 15% in the study subjects and 2.5%.in
the control. The prevalence of hypercholesterolemia (> 210mg/dl) was 12.5 in
the study subjects and o% in the control.
Table
1 Mean
Age, weight, and Body mass index of subjects.
|
HAART |
NO
HAART |
P
value |
Mean
Age (years) |
40.4
± 10.9 |
36.9
± 9.3 |
P>0.05 |
Weight
before treatment (Kg) |
55.2
± 10.6 |
53.6
± 9.7 |
P>0.05 |
Weight
during treatment (Kg) |
63.0
± 12.4 |
56.8
± 10.7 |
P<
0.001 |
Body
mass index |
23.8
± 4.2 |
21.0
±3.3 |
P<
0.001 |
Table 2 Mean
concentration of CD4 and Absolute lymphocyte count of subjects
|
HAART |
NO
HAART |
P
value |
CD4
count (cell/mm3 ) |
344.1
± 171.5 |
179.9
± 64.2 |
P
< 0.0001 |
Absolute
lymphocyte count (cell/mm3) |
529
± 156.7 |
399.3
+ 104.5 |
P
< 0.0001 |
Table
3 Mean
concentration of LIPID Profile of subjects
|
HAART
(mg/dl) |
NO
HAART(mg/dl) |
P
VALUE |
VLDLC |
32.9
± 8.9 |
30.34
± 1.2 |
P
< 0.05 |
HDLC |
29.7
± 9.3 |
35.9
± 13.0 |
P
< 0.05 |
LDLC |
75.9
± 45.8 |
48.9
± 34.4 |
P
< 0.0001 |
Total
cholesterol |
142.3
± 48.6 |
114.6
± 35.8 |
P
< 0.0001 |
Tryglyceride |
163.6
± 44.5 |
150.5
± 37.0 |
P
< 0.05 |
Table 4 Effect
of arm of drug used on cholesterol level of subjects on HAART
|
ARM
1 |
ARM
2 |
P<
0.05
Significant
|
Abnormal Cholesterol
mg/dl
|
23.1
% |
4.5
% |
Normal Cholesterol
mg/dl
|
76.9
% |
95.5
% |
The
cut off point of > 200mg/dl for hypertryglyceridemia and > 210mg/dl for
hypercholesterolemia were based on reference values of National Cholesterol
Education Program(NCEP, 1993) as determined by the expert Panel on the
detection, evaluation, and treatment of high blood cholesterol in adults.
Generally the Trglyceride concentration in both groups are however higher than
the reference value of 150mg/dl in this environment.
Table
5 Effect
of arm of drug used on Tryglyceride level of subjects on HAART
Tryglyceride
mg/dl |
ARM
1 |
ARM
2 |
P
< 0.05
significant
|
Abnormal |
23.1
% |
9.1% |
Normal |
76.9
% |
90.9
% |
DISCUSSIONS
Metabolic
derangements associated with the use of HAART calls for clinical concerns about
their use. Some of these metabolic disorders like Dyslipidemia( abnormally
elevated triglycerides and cholesterol) could lead to heart disease. Debate
continues about whether these outcomes are a direct result of the drugs alone
or whether the disorders are primarily from the course of HIV disease or from
some combination of HIV disease progression plus anti- HIV drug effects. Other
factors which have been identified as effecting the development of these
metabolic complications includes, white race, age of patient, and affluence are
some of the factors that has been suggested by several groups as playing a role
in determining the metabolic changes .(Kotler 1999b, Boyle 2002).
Hyperlipidaemia
defined as an increase in triglyceride and cholesterol levels has been reported
in several studies. In one study, Bernasconi reported that 66% of the patients
on HAART had an increase in triglyceride levels. In addition, 54% of the
patients on protease inhibitors had hypercholesterolemia compared to 19% of the
patients on non-protease inhibitor regimes (Bernasconi 1998).The result of this
study shows that dyslipidaemia is mainly due to the use of the HAART,
especially the Protease Inhibitors. However, the prevalence of dyslipidaemia in
this study is less than what has been reported by Bernasconi in the developed
country. (Bernasconi 1998) Patients who demonstrate elevated total cholesterol
and/or triglyceride levels should be treated appropriately to prevent the
development and progression of atherosclerotic heart disease, stroke, and
pancreatitis. Appropriate dietary and exercise measures remain the foundation
of treatment for hyperlipidaemia. Nutritionist, dietician should therefore be
fully involved in the treatment and care of these patients. Patients with
hyperlipidaemia, and smoke should be counseled on the importance of smoke cessation,
since smoking is a modifiable cardiac risk factor.
The
drug combinations that have protease inhibitors had more effect on the
concentration of the lipids. A number of studies have been performed that
evaluate indirect markers of atherosclerosis. (Kuritzkes and Currier 2003) All
such studies have been small and in conclusive. The most conclusive of these
studies is the Data collection on Adverse Events of Anti-HIV Drugs (DAD) study.
(Friis et al 2003) shows that many well-recognized factors were associated
with myocardial infarction. These include old age, current or former smoking,
previous cardiovascular disease, male sex, higher total serum cholesterol
level, higher triglyceride level, and the presence of diabetes. There is
hyperlipidaemia in the patients on HAART therapy in poor resource limited
settings. Although the values observed are not as high as what is observed in
the developed countries.
It
is important that physicians, nurses, AIDS service providers, and other health
care professionals understand the potential liabilities and limitations of
these drugs. Armed with these limitations, HIV caregivers will be in a position
to more ably assist patients and clients in confronting the challenges posed by
these drugs adverse effects. As a result, people living with HIV infection will
enjoy an improved standard of care characterized by improved clinical outcomes
and a higher quality of life.
Baseline
lipid profile and lipid profile monitoring during therapy especially in the
patients with preexisting cardiac risk factors is recommended in limited
resource countries.
In
conclusion, Dyslipidemia is present in HIV/AIDS patients on HAART in black
population of West Africa, although the level of dyslipidaemia is not as high
as the observed in developed, industialised countries.
REFERENCES
- Bernasconi
E, Carota A, Magenta L, (1998)
Metabolic changes in HIV-infected patients treated with protease
inhibitors.Abstract 12375, 12th World AIDS Conference Geneva,
Switzerland.
- Boyle
BA, (2002) Guide to Management of
Protease Inhibitor. Toxicities and side effects. 1: pg 1
- Carr
A, Samaras K, Burton S, Freund J, Chisholm D, and Cooper D. A (1999) syndrome of peripheral lipodystrophy, hyperlipidemia,
and insulin resistance due to HIV protease inhibitors. AIDS, 12:F51-58.
- Carr
A, Samaras K, Thorisdittir A, Kaufmann G, Chisholm DJ, Cooper DA. (1999) Diagnosis, prediction and natural course of HIV
protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes
mellitus. Lancet , 353:2893-2899.
- Carr
A, Miller J, Law M, Cooper DA.(2000) A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated
with HIV nucleoside analogue therapy: contribution to protease
inhibitor-related lipodystrophy syndrome. AIDS, 14: F25-F32.
- Kotler
D, Schambelam M, (1999) Metabolic Abnormalities: Fat Redistribution, Glucose Metabolism, Cardiovascular
Disease, Medscape HIV/AIDS 5 (supplement): Annual update (b)
- Massip
P, Bonnet E, Cuzin L, Tuech J, Marchou B, Perret B. (1999) Tryglyceride level increases in HIV patients treated
with Protease Inhibitors Especially Concern Atherogenic Apolipoproteins and
Lipoparticles. Abstract 1289, Abstracts 39th Annual ICAAC San
Fransisco CA Session 127.I
- Pallela
FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ,
and Holmberg SD.(1998) Declining
morbidity and mortality among patients with advaced Human Immunodeficiency
virus infection. N Engl J Med, 338(13): 853-60.
- Schapiro
JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, and Merigan TC.(1996) The effect of high dose-saquinavir on viral load and
CD4+ T cell counts in HIV infected patients. Ann Intern Med 1996, 124(12):
1039-50
- Kuritzkes
DR, Currier J. (2003) Cardiovascular
risk factors and antiretroviral therapy. N Engl J Med.; 348: 679-680.
- Phair
JP and Kotler DP (2005) Body shape
changes associated with antiretroviral therapy: Insights into pathogenesis and
epidemiology. IMed Options
- Riddler
SA (2003) Impact of HIV
infection and HAART on serum lipids in men. JAMA June 11 289: 2978-82.
- Behrens
G and Schmidt RE (2005) Lipodystrophy
syndrome . HIV Medicine.
- National
Cholesterol Education Program (NCEP) (1993) Expert Panel on the Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel II). JAMA; 269: 3015-23.
- Friis-Moller,
Weber R, Reiss P, Thiebaut R, Kirk O, (2003) Cardiovascular disease risk factors in HIV patients. Association with
antiretroviral Therapy. Results from DAD study. AIDS 17: 1179-1193
- Friedewald
WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low density lipoprotein cholesterol in
plasma without the use of the preperative ultracentrifuge. Clin. Chem 18:
499-502.
- Clinical
Laboratry Diagnostics. (1998) 1st Edition Lothar Thomas ed. TH-Books Verlagsgesellschaft mbH, Frankfurt/Main,
Germany. P 169
- Tietz,
Nader R, Paul S, Bachorik, John J A(1999) Lipid Lipoprotein and Apolipoproteins. In: Tietz Textbook of clinical
Chemistry, ed. Burtis C. A. and Ashwood, E.R 839 -843
Copyright 2008 - Ibadan Biomedical Communications Group
|